# A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

Study · id `cardio:ct-nct04712669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04712669](<https://clinicaltrials.gov/study/NCT04712669>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04712669

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT04712669. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-15 (actual); primary completion 2023-06-05 (actual). Results posted on 2025-06-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT04712669, source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)
- Started: 2021-03-15 (actual) (ClinicalTrials.gov record NCT04712669, source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)
- Primary completion: 2023-06-05 (actual) (ClinicalTrials.gov record NCT04712669, source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)
- Completion: 2023-08-28 (actual) (ClinicalTrials.gov record NCT04712669, source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)
- Results first posted: 2025-06-04 (ClinicalTrials.gov record NCT04712669, source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)
- Countries: United States; Austria; Belgium; Bosnia & Herzegovina; Bulgaria; Canada; Czechia; France; Germany; Italy; Latvia; Moldova; Poland; Serbia; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT04712669, source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04712669-2025-06-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): rodatristat ethyl 300 mg tablet BID
- Intervention (Drug): rodatristat ethyl 600 mg BID
- Intervention (Drug): Placebo
- Lead sponsor: Altavant Sciences GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial (`cardio:pubmed-39307144`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial (`cardio:pubmed-41973984`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e0048fabfed4d6ad94673c75345ddba103bf9dd2cdbba0ab5cac77dd07e8615b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
